E. David Crawford, MD

E. David Crawford, MD

Editor-in-Chief
Grand Rounds in Urology
Professor of Urology
University of California, San Diego

San Diego, California

E. David Crawford, MD, is a Professor of Urology at the University of California, San Diego. He is an internationally renowned urologist, and the former distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford is an expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has authored many scientific articles, as well as textbooks and book chapters. He has served as an editorial reviewer or consultant for many publications, including Urology, Journal of Urology, and the Journal of Clinical Oncology. Dr. Crawford is a member of many organizations, including the American Society of Clinical Oncology (ASCO), the American Urological Association (AUA), and the American Association for the Advancement of Science (AAAS). He is the Founder and Chairman of the Prostate Conditions Education Council, which is responsible for raising awareness and screening of millions of men for prostate health issues. He has received many awards, including the CaP CURE Annual Award for Scientific Presentation, and has twice been presented with a “Freddie Award” for best medical documentaries. He has long been recognized as one of the Best Doctors of America and is recognized as one of the top 20 urologists in the country for men by Men’s Health Magazine.

Articles by E. David Crawford, MD

Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate Cancer

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, and Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology and Assistant Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, present a Point-Counterpoint on the relative value of genomics and biomarkers in prostate cancer risk stratification. Dr. Crawford, presenting the pro side, argues that doctors need to do biomarker testing to know which patients to biopsy, follow closely, and treat with radiation. Dr. Bryce, presenting the con side, contends that while germline testing is beneficial, other biomarker tests have inconsistent results for prostate cancer patients.

Read More

Challenging Cases in Advanced Prostate Cancer- mHSPC

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at University of California, San Diego, gives his expertise on next generation biomarkers in prostate cancer screening. Firstly, Dr. Crawford qualifies the new standard of PSA >1.5 ng/mL, specifically how it aids in early detection of disease and acts as a surrogate for BPH, prostate cancer, and prostatitis. Following this, Dr. Crawford reviews the clinical needs and genomic markers of prostate cancer. In conclusion, he describes his algorithm for PSA screening.

Read More

Next Generation Biomarkers – As Reflex, Combination, or First Line?

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at University of California, San Diego, gives his expertise on next generation biomarkers in prostate cancer screening. Firstly, Dr. Crawford qualifies the new standard of PSA >1.5 ng/mL, specifically how it aids in early detection of disease and acts as a surrogate for BPH, prostate cancer, and prostatitis. Following this, Dr. Crawford reviews the clinical needs and genomic markers of prostate cancer. In conclusion, he describes his algorithm for PSA screening.

Read More

Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study

Daniel W. Lin, MD, and Eric A. Klein, MD, present a point-counterpoint on the conclusions of Dr. Lin’s recently published results of Canary PASS (Prostate Active Surveillance Study), which looked at the ability of the Oncotype DX genomic prostate score (GPS) for predicting adverse pathology (AP) in primarily low-risk prostate cancer patients undergoing active surveillance. Following each presentation, Dr. Lin and Dr. Klein also discuss several follow-up questions related to the study and, more broadly, the future of prostate cancer treatment with E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology.

Read More

Join the GRU Community

- Why Join? -